SCHEMBL7227773

SCHEMBL7227773

COc1ccc2c(c1)C(c1ccccc1)=NNC(=S)C2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.47
HTT P42858 1/20 0.47
CHRM1 P11229 1/20 0.45
NPY5R Q15761 2/20 0.44
L3MBTL1 Q9Y468 4/20 0.43
KMT2A Q03164 3/20 0.43
TDP1 Q9NUW8 2/20 0.43
MEN1 O00255 2/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA4 P22748 1/20 0.42
CA6 P23280 1/20 0.42
PDGFRB P09619 1/20 0.42
PLA2G1B P04054 1/20 0.42
ATG4B Q9Y4P1 1/20 0.42
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
KDM4E B2RXH2 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7228807 0.88 MAPK1 (0.45) MAPTHTTL3MBTL1KMT2ATDP1
SCHEMBL7227570 0.85 CYP1A2 (0.58) MAPTHTTNPY5RL3MBTL1CA1
SCHEMBL7225951 0.83 MAPT (0.52) MAPTHTTL3MBTL1KMT2ATDP1
SCHEMBL8452460 0.80 CYP1A2 (0.56) MAPTHTTNPY5RL3MBTL1KMT2A
SCHEMBL7235789 0.75 GRIA2 (0.47) MAPTKMT2ATDP1MEN1CA1
SCHEMBL7611763 0.75 ALDH1A1 (0.45) MAPTCHRM1NPY5RL3MBTL1KMT2A
SCHEMBL2037162 0.73 CYP1A2 (0.74) CA1CA2CYP1A2CYP3A4CYP2C9
SCHEMBL7234430 0.73 CYP1A2 (0.60) MAPTL3MBTL1KMT2ATDP1MEN1
SCHEMBL7605981 0.72 CYP1A2 (0.76) MAPTL3MBTL1KMT2ATDP1MEN1
SCHEMBL2340188 0.71 ALDH1A1 (0.62) NPY5RCA1CA2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6600036-B2 Treating diseases of the central nervous system. SCHERING AKTIENGESELLSCHAFT (DE) 2003-07-29 US disclosed
US-20020052364-A1 Condensed 2,3-benzodiazepine derivatives and their use as AMPA-receptor inhibitors BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2002-05-02 US disclosed
EP-0888356-B1 CONDENSED 2,3-BENZODIAZEPINE DERIVATIVES AND THEIR USE AS AMPA-RECEPTOR INHIBITORS SCHERING AG (DE) 2002-03-20 EP disclosed
US-6323197-B1 NON-COMPETITIVE INHIBITING OF THE AMPA RECEPTORS, THESE COMPOUNDS CAN BE USED AS MEDICAMENTS FOR TREATMENT OF THE CENTRAL NERVOUS SYSTEM SCHERING AKTIENGESELLSCHAFT (DE) 2001-11-27 US disclosed
EP-0888356-A1 CONDENSED 2,3-BENZODIAZEPINE DERIVATIVES AND THEIR USE AS AMPA-RECEPTOR INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 1999-01-07 EP disclosed
WO-1997028163-A1 CONDENSED 2,3-BENZODIAZEPINE DERIVATIVES AND THEIR USE AS AMPA-RECEPTOR INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 1997-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052364-A1 Condensed 2,3-benzodiazepine derivatives and their use as AMPA-receptor inhibitors GABRE, GABRA2, GABRB2 MAPT 999/4885HTT 3279/4885CHRM1 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.